Articles tagged "Immunosuppression"

2018 American Transplant Congress
Long-Term Effects of Ketoconazole in Rapid Tacrolimus Metabolizers Post-Renal Transplantation
J. Ching,¹ S. Anders,¹ M. Janusek,¹ L. Hutchinson,¹ A. Freeman,¹ U. Patel,¹ A. Mohammed,⁴ H. Bohorquez.^2,3
¹Department of Pharmacy, Ochsner Clinical Foundation, New Orleans, LA; ²Multi-Organ Transplant Institute, Ochsner Clinical Foundation, New Orleans, LA; ³The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA; ⁴Academic Center, Ochsner Clinical Foundation, New Orleans, LA.
Introduction: Genetic polymorphisms in cytochrome P-450 enzymes can cause variations in tacrolimus (tac) metabolism. Ketoconazole (keto), a potent CYP450 and P-glycoprotein inhibitor, can be used…
2018 American Transplant Congress
Immunosuppression Does Not Affect Adverse Pathological Outcomes in Men Who Underwent Radical Prostatectomy
M. Eltemamy, A. Elshafei, Y. Nyame, A. Crane, A. Wee, V. Krishnamurthi, E. Klein, S. Jones.
Cleveland Clinic, Cleveland.
Introduction: The impact of imuunosuppression (IS) on biological aggressiveness of cancer prostate (PCa) is unclear. We aim to assess the adverse pathological (AP) outcomes in…
2018 American Transplant Congress
The Net State of Immunosuppression in Septuagenarian Liver Transplant Recipients: Balancing Rejection and Infection Risks
J. Casale,¹ J. Clark,¹ B. Ravichandran,¹ J. LaMattina.²
¹Pharmacy, University of Maryland Medical Center, Baltimore; ²University of Maryland School of Medicine, Baltimore.
Purpose: Careful patient selection and perioperative management have allowed for successful liver transplantation in elderly patients. Elderly patients may be more susceptible to the infectious…
2018 American Transplant Congress
Tacrolimus-Based Maintenance Immunosuppression Decreases the Number of Peripheral Blood Transitional B Cells in Nonhuman Primates
J. Paster, K. Pruner, M. Hanekamp, J. O., W. Sommer, K. Robins, A. Bean, G. Benichou, J. Madsen.
Center for Transplantation Sciences, Mass General Hospital, Boston, MA.
IntroductionElevated frequencies of transitional B cells have been reported in patients tolerant of renal allografts, as defined by stable graft function after withdrawal of immunosuppression…
2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
S. Mulgaonkar,¹ Y. Qazi,¹ D. Kim,¹ V. Peddi,¹ K. McCague,² D. Patel,² A. Wiseman.¹
¹TRANSFORM Study Group, Livingston; ²Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…
2018 American Transplant Congress
Approaches to Prevention of Antibody Rebound after HLA Sensitization in a Mouse Model
I. Kim, G. Wu, N-.N. Chai, A. Klein, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Control of donor specific antibodies (DSA) is critical for prevention of antibody mediated rejection (ABMR). Removal of DSAs with PLEX often results in significant…
2018 American Transplant Congress
Early Steroid Withdrawal and Kidney Transplant Outcomes for Recipients with Delayed Graft Function
S. Bae, A. Massie, X. Luo, J. Garonzik Wang, D. Segev.
Johns Hopkins, Baltimore, MD.
Current guidelines suggest early steroid withdrawal (ESW) regimen for kidney transplant (KT) recipients with low immunological risk. Delayed graft function (DGF) is a risk factor…
2018 American Transplant Congress
The Impact of Childhood Solid Organ Transplantation on B-Cell Maturation
L. Ionescu,¹ T. Blydt-Hansen,² B. Foster,⁷ S. Mital,³ L. Hamiwka,⁵ U. Allan,³ V. Phan,⁴ P. Birk,⁶ C. Morgan,¹ S. Urschel.¹
¹U of Alberta, Edmonton, Canada; ²U of BC, Vancouver, Canada; ³Hospital for Sick Children, Toronto, Canada; ⁴U de Montreal, Montreal, Canada; ⁵U of Calgary, Calgary, Canada; ⁶U of Manitoba, Winnipeg, Canada; ⁷McGill University, Montreal, Canada.
Background:The developing immune system of childhood promotes better graft acceptance and longevity but also higher risk for infections and post-transplant (Tx) lymphoproliferative disorders. This may…
2018 American Transplant Congress
Influence of mTOR Inhibitors on Metabolic Outcomes One Year after Kidney Transplantation: The Role of Pre-Transplantation Diabetes
D. Cucchiari,¹ S. Karam,² P. Ventura-Aguiar,¹ J. Torregrosa,¹ F. Diekmann.¹
¹Renal Transplant Unit, Hospital Clínic, Barcelona, Spain; ²Department of Medicine, Saint George Hospital, Beirut, Lebanon.
INTRODUCTION: mTOR inhibitors alter lipids and carbohydrate metabolism in kidney transplant recipients. Little is known if there is any difference between patients who were already…
2018 American Transplant Congress
Genome-Wide Association Study of Tacrolimus Dose in Pediatric Solid Organ Transplant Recipients in the CNTRP POSITIVE Study
S. Min,¹ T. Papaz,¹ T. Blydt-Hansen,³ O. Lee,¹ U. Allen,¹ P. Birk,² H. Grasemann,¹ L. Hamiwka,⁴ C. Litalien,⁵ V. Ng,¹ R. Parekh,¹ K. Tinckam,⁶ S. Urschel,⁷ B. Foster,⁸ S. Mital.¹
¹The Hospital for Sick Children, Toronto, Canada; ²Winnipeg Children's Hospital, Winnipeg, Canada; ³BC Children's Hospital, Vancouver, Canada; ⁴Alberta Children's Hospital, Calgary, Canada; ⁵CHU Ste-Justine, Montreal, Canada; ⁶University Health Network, Toronto, Canada; ⁷Stollery Children's Hospital, Edmonton, Canada; ⁸Montreal Children's Hospital, Montreal, Canada.
PURPOSE: There are significant challenges in achieving therapeutic tacrolimus (Tac) concentrations after transplant. We explored variants associated with tacrolimus dose requirements in pediatric solid organ…